[1] Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363 (2009). DOI: 10.1371/journal.ppat.1000363
[2] Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837–846 (2009). DOI: 10.1086/597126
[3] Prezioso C, Pietropaolo V, Moens U, Ciotti M. JC polyomavirus: a short review or its biology, its association with progressive multifocal leukoencephalopathy, and the diagnostic value of different methods to manifest its activity of presence. Exp Rev Mol Diagn 23:143.157 (2023). DOI: 10.1080/14737159.2023.2179394
[4] Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, Major EO, Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471–506 (2012). DOI: 10.1128/CMR.05031-11
[5] Wollebo HS, White MK, Gordon J, Berger JR, Khalili K. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560–570 (2015). DOI: 10.1002/ana.24371
[6] Schweitzer F, Laurent S, Cortese I, Fink GR, Silling S, Skripuletz T, Metz I, Wattjes MP, Warnke C. Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy. Neurology 101:700-713 (2023). DOI: 10.1212/WNL.0000000000207622
[7] Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80: 1430-1438. DOI: 10.1212/WNL.0b013e31828c2fa1
[8] Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17:37-51 (2021). DOI: 10.1038/s41582-020-00427-y